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Abstract
Objective: To investigate whether the strength of the association between mag-
netic resonance imaging (MRI) metrics and cognitive outcomes differs between
various multiple sclerosis subpopulations. Methods: A total of 1052 patients
were included in this large cross-sectional study. Brain MRI (T1 and T2 lesion
volume and brain parenchymal fraction) and neuropsychological assessment
(Brief International Cognitive Assessment for Multiple Sclerosis and Paced
Auditory Serial Addition Test) were performed. Results: Weak correlations
between cognitive domains and MRI measures were observed in younger
patients (age≤30 years; absolute Spearman’s rho = 0.05–0.21), with short dis-
ease duration (<2 years; rho = 0.01–0.21), low Expanded Disability Status Scale
[EDSS] (≤1.5; rho = 0.08–0.18), low T2 lesion volume (lowest quartile;
<0.59 mL; rho = 0.01–0.20), and high brain parenchymal fraction (highest
quartile; >86.66; rho = 0.01–0.16). Stronger correlations between cognitive
domains and MRI measures were observed in older patients (age>50 years;
rho = 0.24–0.50), with longer disease duration (>15 years; rho = 0.26–0.53),
higher EDSS (≥5.0; rho = 0.23–0.39), greater T2 lesion volume (highest quar-
tile; >5.33 mL; rho = 0.16–0.32), and lower brain parenchymal fraction (lowest
quartile; <83.71; rho = 0.13–0.46). The majority of these observed results were
confirmed by significant interactions (P ≤ 0.01) using continuous variables.
Interpretation: The association between structural brain damage and functional
cognitive impairment is substantially weaker in multiple sclerosis patients with
a low disease burden. Therefore, disease stage should be taken into considera-
tion when interpreting associations between structural and cognitive measures
in clinical trials, research studies, and clinical practice.
Introduction
The clinical presentation of multiple sclerosis (MS)
includes a wide range of physical, as well as cognitive,
signs, and symptoms.1–4 In particular, cognitive impair-
ment has recently been increasingly recognized as an
important determinant of employment status and associ-
ated societal costs,5,6 negatively impacting social function-
ing, coping, quality of life, and treatment adherence
among patients with MS.7
In this context, associations between brain imaging
measures and cognitive functioning have been observed
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in patients with MS.1,3 Particularly, T1 lesion volume
(T1-LV) and T2 lesion volume (T2-LV),8,9 damage of
normal-appearing white matter,10,11 occurrence of cortical
lesions,12,13 and gray matter,14,15 or thalamic atrophy11,16
have been suggested as important brain imaging correlates
of cognitive impairment.
Even though most previous studies have shown a rela-
tionship between lesion burden or brain atrophy on MRI
and cognitive impairment, there are still a number of studies
that did not report such associations.2,17–26 In addition, the
magnitude of reported associations varies wildly between
studies.1,3,27 By further examining these inconsistencies, the
interpretation of associations between structural and cogni-
tive metrics can possibly be improved by identifying contex-
tual determinants of the strength of these associations.
Most previous studies investigating MRI correlates of cog-
nitive impairment included small samples or heterogeneous
MS populations. This study was conducted using a large and
clinically well-described observational cohort of patients
with predominantly relapsing–remitting MS, mostly on dis-
ease-modifying treatments. We hypothesized that the
strength of the association between brain MRI and cognitive
measures in MS varies as a function of disease stage, cumula-
tive disease burden, and patient characteristics.
Materials and Methods
Study population
The Grant Quantitative study was a 3-year prospective
observational study investigating a comprehensive battery
of clinical and paraclinical measures set up to evaluate MS
progression in routine clinical practice. Inclusion criteria
were as follows: clinically isolated syndrome or clinically
definite MS confirmed by MRI and cerebrospinal fluid
examination, Czech fluent speaker, and age ≥18. Exclusion
criteria were as follows: signs and symptoms suggestive of a
disease other than MS or a serious psychiatric disorder.
Enrollment started in June 2012. For the present analysis,
the database was locked in October 2015. The study proto-
col was approved by the Medical Ethics Committee of the
General University Hospital in Prague and First Faculty of
Medicine, Charles University in Prague, Czech Republic.
All patients provided their written informed consent.
MR image acquisition and analysis
This study used MRI scans performed within 3 months
before or after neuropsychological assessment. All MRI
scans were performed on the same scanner (1.5-Tesla Gyro-
scan; Philips Medical Systems, Best, the Netherlands) in the
Department of Radiodiagnostics at General University
Hospital in Prague using the same protocol. The
standardized protocol consisted of two sequences: fluid-
attenuated inversion recovery (FLAIR) and T1-weighted
three-dimensional turbo field echo (T1-WI/3D/TFE). Con-
tiguous slices covering the whole brain were acquired with
the following parameters: FLAIR sequence (time to
echo = 140 msec, time to repetition 11,000 msec, inver-
sion time 2600 msec, matrix size 256 9 181, flip angle 90,
slice thickness/gap=1.5/0 mm, field of view=256 mm), and
T1-WI/3D/TFE (time to echo/time to repetition: 5/
25 msec, flip angle =30, matrix size 256 9 256, slice thick-
ness/gap=1.0/0 mm, field of view = 256 mm).
Volumetric image analysis was performed in the
Department of Radiodiagnostics, General University
Hospital, in Prague using ScanView. ScanView is a semi-
automated software tool for measurement of T1-LV and
T2-LV, BPF (brain parenchymal fraction) whole brain,
and corpus callosum volumes via segmentation-based
techniques. A detailed description of the ScanView was
published previously.28
T2-LVwasmeasured from the FLAIR sequence.WB volume
was measured from the T1-WI/TFE 3D sequence. Intracranial
volume was calculated as the sum of the total brain parenchy-
mal volume and the total intraventricular and subarachnoidal
cerebrospinal fluid volume. Normalized compartment volume
was calculated as follows: (BPF) = whole-brain parenchymal
volume/intracranial volume.4, 28, 29
Neuropsychological assessment
All participants were tested using the Czech-validated ver-
sion of the Brief International Cognitive Assessment for
Multiple Sclerosis (BICAMS).30,31 Cognitive processing
speed was assessed with the Symbol Digit Modalities Test
(SDMT) where stimuli were presented visually and only
the oral response form was recorded. Memory was tested
with the Brief Visuospatial Memory Test Revised
(BVMTR) in the visual modality, and the California Ver-
bal Learning Test Second Edition (CVLT2) in the audi-
tory sphere. For both Brief Visuospatial Memory Test
Revised and California Verbal Learning Test Second Edi-
tion, only the initial learning trials of each test were
administered. All but of 12 patients were also tested with
the three-second interval Paced Auditory Serial Addition
Test (PASAT), thus providing a second test of cognitive
processing speed, although in auditory modality.
Impairment for a single test was defined at the level of
1.5 standard deviation (i.e., z-score <1.5 compared with a
healthy population), using the regression-based norms of
134 healthy controls adjusted for age, sex, and education.
Raw scores of the cognitive tests were used in the statisti-
cal models and presented results. Patients were evaluated
as cognitively impaired when scoring outside the normal
range in one or more of the BICAMS tests.30,31
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For the assessment of depressive symptoms, the Beck
Depression Inventory-II (BDI-II) was used.
Statistical analysis
All analyses were performed using SPSS 22 (IBM,
Armonk, NY) and Statistica 12 (Statsoft, Tulsa, OK).
Normality of distribution was assessed using the Kol-
mogorov–Smirnov method and visual inspection of his-
tograms. In parametric analyses, non-normally distributed
variables were transformed (T1-LV and T2-LV using
Cox–Box transformation, and BDI-II using logarithmic
transformation and PASAT using logit transformation).
Associations between the cognitive (SDMT, BVMTR,
CVLT2, PASAT) and MRI (T1-LV, T2-LV, and BPF)
measures in MS subgroups were evaluated using nonpara-
metric Spearman’s correlation coefficients (rho) to elimi-
nate effects of non-normal distribution and potential
presence of outliers.
The primary analysis consisted of interaction models of
selected continuous variables (age, disease duration,
Expanded Disability Status Scale [EDSS], T2-LV, and
BPF) and MRI measures, in association with cognitive
performance. These analyses were conducted to evaluate
the relationship between disease or patient characteristics
and the strength of the associations between brain MRI,
with cognitive measures. In the next step, multivariable
models with interaction terms were adjusted for the
potential confounders such as sex, age, education, depres-
sion, and treatment status. Table S1 provides detailed
description of the adjusted multivariable models with the
interaction term.
Multivariable linear regression analyses were used to
test the relationships between cognitive and MRI mea-
sures adjusted for sex, age or disease duration, education,
depression, and treatment status. Only treatment status
was set as a categorical variable with the following three
categories: injectable disease-modifying treatments (glati-
ramer acetate, interferons b, intravenous immunoglobu-
lin), dimethyl fumarate and teriflunomide, second-line
disease-modifying treatments (alemtuzumab, fingolimod,
natalizumab, mitoxantrone, rituximab), and no disease-
modifying treatment. Because of multicolinearity between
the age and disease duration, multivariable models were
adjusted only for age.
Importantly, MS patient subgroups were stratified
according to their age, disease duration, EDSS, T2-LV, or
BPF (presented in Figures 1 and 2). This was established
arbitrarily and used mainly for graphical purposes to
show differences in strength of correlations among differ-
ent MS subgroups.
To control false discovery rate, Benjamini–Hochberg
procedure with P < 0.01 was applied.
Results
Demographic, clinical, and MRI
characteristics
Of the 1253 patients enrolled in the study, 1052 had all cog-
nitive and MRI data available and were included in the anal-
ysis. Of these, 867 (82%) patients were treated with disease-
modifying treatment. Median EDSS was 2.0, and average
disease duration was 10.0 years. Cognitive impairment
(abnormal outcome of BICAMS battery) was present in 282
(27%) of patients. Abnormal outcome of BICAMS battery
was driven mostly by abnormal SDMT, which was present
in 229 (81%) of patients with cognitive impairment. Table 1
describes details of demographic, clinical, neuropsychologi-
cal, and MRI characteristics of the patient cohort.
Correlation between cognitive and MRI
measures
All associations between the cognitive domains and all
MRI measures reached statistical significance (absolute
Spearman’s rho≥0.24; P < 0.001). The strongest correla-
tions between cognitive and MRI measures were identified
among SDMT and T1-LV, T2-LV, and BPF (rho≥0.39;
standardized beta ≥0.36; P < 0.001) (Table 2). In addi-
tion, we found some sex differences in correlations
between cognitive and MRI measures (Table S2). Sample
size needed to observe significant (P < 0.05) Spearman’s
correlations between cognitive (SDMT) and brain MRI
measures in different MS subgroups is shown in Table 3.
Adjusted regression analysis between
cognitive and MRI measures
The associations between cognitive and MRI measures
were confirmed in multivariable models adjusted for sex,
age, education, depression, and treatment status
(P < 0.001). All covariates, such as sex, age, education,
depression, and MRI measures, were independently (all
P < 0.0001) correlated with SDMT in the multivariable
model. More details about the independent correlates of
the other cognitive subtests, including BVMTR, CVLT2,
and PASAT, are provided in Table S3.
Correlation between cognitive and MRI
measures stratified by age, disease
duration, disability status, lesion load, and
brain atrophy subgroups
Overall, the strength of associations between the cognitive
domains and MRI measures increased with greater age,
disease duration, EDSS step, T2-LV, and lower BPF.
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In stratified analyses, Spearman’s correlation coeffi-
cients between cognitive domains and MRI measures in
patients >50 years of age were between rho = 0.24 and
rho = 0.50. On the other hand, absolute rho values were
considerably lower (between 0.05 and 0.21) in patients
≤30 years of age. An effect of higher age was most promi-
nently observed between T1-LV or T2-LV and PASAT,
where the rho difference between patients >50 years and
patients ≤30 years was between 0.41 and 0.42.
Correlation coefficients between cognitive domains and
MRI measures in patients with disease duration >15 years
were between rho = 0.26 and rho = 0.53. In contrast, rho
values were considerably lower (between 0.01 and 0.21) in
patients with disease duration <2 years. An effect of
longer disease duration was most prominently observed
between T1-LV and SDMT, where the rho difference
between patients with disease duration >15 years and
patients with disease duration <2 years was 0.42.
Correlation coefficients between the cognitive
domains and MRI measures in patients with EDSS≥5.0
were between rho = 0.23 and rho = 0.39. Rho values
were considerably lower (between 0.08 and 0.18) in
patients with EDSS≤1.5. This progressive effect of
greater EDSS was observed for all cognitive measures,
where the highest rho difference between patients with
EDSS≥5.0 and patients with EDSS ≤1.5 was between
0.21 and 0.23.
Correlation coefficients between cognitive domains and
MRI measures in patients within the highest quartile of
T2-LV (>5.33 mL) were between rho = 0.16 and
rho = 0.32. Rho values were considerably lower (between
0.01 and 0.20) in patients within the lowest quartile of
T2-LV (<0.59 mL). An effect of greater T2-LV was most
apparent for associations between T1-LV or T2-LV and
SDMT, where the rho difference between patients with
the lowest and the highest T2-LV quartile was 0.28.
Figure 1. The strength of associations between brain MRI (brain parenchymal fraction, T1 and T2 lesion volume) and cognitive measures (Symbol
Digit Modalities Test, three-second interval Paced Auditory Serial Addition Test, Brief Visuospatial Memory Test Revised, California Verbal Learning
Test Second Edition) in multiple sclerosis subpopulations. Subgroups of patients stratified by (A) age, (B) disease duration, (C) Expanded Disability
Status Scale, (D) T2 lesion volume, or (E) brain parenchymal fraction were used for graphical purposes (the primary analysis of interaction models
was performed using continuous variables).
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Correlation coefficients between the cognitive domains
and MRI measures in patients within the lowest quartile of
BPF (<83.71) were between rho = 0.13 and rho = 0.46.
Absolute rho values were considerably lower (between 0.01
and 0.16) in patients in the highest quartile of BPF (>86.66).
An effect of lower BPF was most apparent for associations
between T1-LV or T2-LV and SDMT, where the rho differ-
ence between patients with the lowest and the highest BPF
quartile was between 0.27 and 0.39 (Figure 1, Figure S1).
Interaction effects of age, disease duration,
disability status, lesion load, and brain
atrophy on the associations between
cognitive and MRI measures
There were significant interactions of variables indicating
disease burden (age, disease duration, and EDSS) and
MRI measures, predicting cognitive impairment. How-
ever, in multivariable models adjusted for sex, age,
Figure 2. (A-B) The threshold concept of brain pathology for the manifestation of a cognitive decline in multiple sclerosis patients. (C) The
strength of associations between brain parenchymal fraction and Symbol Digit Modalities Test scores in patients within the lowest and the highest
quartile of T2 lesion volume.
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education, depression, and treatment status, we found
only a limited number of interaction effects with P < 0.01
after Benjamini–Hochberg correction. There were also sig-
nificant interactions of variables indicating radiological
disease burden (T2-LV and BPF) and MRI measures, pre-
dicting cognitive impairment. Adjusted multivariable
Table 1. Baseline demographic, clinical, neuropsychological, and MRI
characteristics of the sample.
Sample characteristics N = 1052
Demographic
Number of females 734 (70%)
Age in years 38.1  8.8; 37.5
Education 14.7  3.0; 14.0
Unemployed 233 (22%)
Employed or students 819 (78%)
Disease duration at baseline (years) 10.0  7.3; 8.1
Clinical
Expanded Disability Status Scale1 2.5  1.3; 2.0; (0-6.5)
No disease-modifying treatment 185 (17%)
First-line disease-modifying
treatment2
670 (64%)
Second-line disease-modifying
treatment3
197 (19%)
Cognitive
Symbol Digit Modalities Test4 55.3  11.6; 56.0 (22%)
Three-second interval Paced
Auditory Serial Addition Test5
47.8  11.4; 50.0
Brief Visuospatial
Memory Test revisited4
27.6  6.4; 29.0 (10%)
California Verbal Learning
Test Second Edition4
59.2  11.7; 61.0 (5%)
Abnormal Brief International
Cognitive Assessment for
Multiple Sclerosis (BICAMS)6
282 (27%)
Beck Depression Inventory-II7 7.4  7.2; 5.0 (183; 17%)
MRI
Brain parenchymal fraction (%) 85.1  2.2; 85.4
T1 lesion volume (ml) 1.6  2.0; 0.8
T2 lesion volume (ml) 4.8  8.1; 1.7
Unless otherwise indicated, all data are reported as mean  standard
deviation, median.
1Data in parentheses are ranges.
2Injectable disease-modifying treatment (glatiramer acetate, interfer-
ons, intravenous immunoglobulins), dimethyl fumarate, teriflunomide.
3Second-line disease-modifying treatment: alemtuzumab, fingolimod,
natalizumab, mitoxantrone, rituximab.
4Data in parentheses are percentages of patients with abnormal test
outcome.
512 subjects have no Three-second interval Paced Auditory Serial
Addition Test.
6Abnormal Brief International Cognitive Assessment for Multiple
Sclerosis was defined as scoring outside the normal range in ≥1 Brief
International Cognitive Assessment for Multiple Sclerosis subtests.
7Data in parentheses are number and percentage of patients with
Beck Depression Inventory-II score >14.
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models confirmed these observations by demonstrating
significant interactions (P < 0.01) between the grouping
MRI variables indicating radiological disease severity
(quartiles of T2-LV and BPF) and MRI measures (T1-LV,
T2-LV, and BPF; Figure 1, Table 4).
Discussion
Although most previous MS studies have observed associ-
ations between brain atrophy or MRI lesion measures and
cognitive performance, the magnitude of these associa-
tions was highly variable between studies.1,9,27 It has been
suggested that heterogeneity of the utilized imaging and
cognitive metrics is primarily responsible for this variabil-
ity.27 It is, however, not yet clear whether this association
varies with respect to patient characteristics as well.
In this cross-sectional study of 1052 well-defined
patients with MS, we found that the strength of associa-
tions between volumetric brain MRI and cognitive mea-
sures increases with clinically and radiologically more
advanced disease. Correlations between brain MRI and
cognitive metrics were relatively low in patients with a
low disease burden (i.e., short disease duration or young
age, low EDSS, low lesion load, and low brain atrophy).
In contrast, considerably stronger correlations between
brain MRI and cognitive measures were found in patients
with a high disease burden (i.e., long disease duration or
older age, high EDSS, high lesion load, or high brain
atrophy).
The observed trends of increasing radiological burden
were confirmed by interaction terms with quantitative MRI
metrics (T1-LV, T2-LV, and BPF) versus cognitive tests.
Even though patients with older age, longer disease dura-
tion, or higher EDSS also showed more pronounced corre-
lations between MRI and cognitive metrics, the majority of
interactions between age, disease duration, or EDSS and
MRI measures in multivariable models predicting cognitive
performance were not significant after correction for false
discovery rate. We hypothesize this may be explained by
the fact that associations between age or disease duration
and cumulative disease burden are only indirect and that
EDSS (as a measure of clinical disease burden) is less objec-
tive and a relatively inaccurate measure of disease burden,32
as compared to volumetric MRI measures.33
Taken together, the strong associations between MRI
and cognitive metrics in more advanced disease imply
there is a greater sensitivity of cognitive performance to
structural changes in patients with already greater cumula-
tive structural brain damage. We suggest that cognitive
decline does not become clinically apparent until a certain
threshold of substantial structural brain changes has been
reached. The concept that a threshold for brain pathology
needs to be met before cognitive decline becomes clinically
apparent (Figure 2) means that irreversible axonal damage
and brain tissue loss under a certain threshold may accu-
mulate in relatively asymptomatic patients. Once the cog-
nitive brain capacity has been surpassed and functional
compensatory mechanisms fail, cognitive disability may
become clinically apparent.34–36 This could explain why
patients with some but minor brain atrophy or with a
small lesion burden often show only limited cognitive
deterioration relative to brain pathology.37 In contrast,
patients with significant preexisting brain damage are rela-
tively more sensitive to any additional structural brain
damage.
It has been established that the sensitivity of cognitive
and MRI measures to minor changes of cognitive perfor-
mance or brain pathology is limited due to a number of
factors influencing measurement accuracy. For example,
Table 3. Sample size needed to observe significant (P < 0.05) correla-
tions between cognitive (Symbol Digit Modalities Test) and brain MRI
measures in different patient subgroups.
MRI measures
Disease duration (years)
<2 2–5 5–10 10–15 >15
Brain parenchymal
fraction
88 47 36 44 24
T2 lesion volume 88 107 41 26 15
Age (years)
≤30 ≤35 ≤40 ≤50 >50
Brain parenchymal
fraction
151 50 36 22 34
T2 lesion volume 88 39 34 19 29
Expanded Disability Status Scale (steps)
0–1.5 2.0–2.5 3.0–3.5 4.0–4.5 ≥5.0
Brain parenchymal
fraction
119 80 21 39 50
T2 lesion volume 119 107 18 28 26
T2 lesion volume (quartiles)
Low Mid–low Mid–high High –
Brain parenchymal
fraction
>200 107 97 50 –
T2 lesion volume >200 >200 >200 41 –
Brain parenchymal fraction (quartiles)
High Mid–high Mid–low Low –
Brain parenchymal
fraction
>200 >200 >200 58 –
T2 lesion volume >200 151 50 19 –
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actual lesion or brain volume differences between two sub-
jects with a low radiological disease burden might be
observed as comparable due to the fact that lesion or brain
volume measurement can be error influenced by biological
and technical biases. The same could also be a factor in cog-
nitive measures in patients with a relative preserved cogni-
tive performance. Here, an actual cognitive difference
between two subjects might be observed as comparable due
to cognitive performance measurement error or physiologi-
cal fluctuations influenced by variety of factors such as
motivation and other personality factors, time of day, and
fatigue level. Hence, it is not particularly surprising that the
accuracy of correlations between MRI and cognitive mea-
sures in patients with low radiological and cognitive disease
burden may be affected substantially.
Findings from this study could help elucidate the rea-
son for the lack of associations found in the literature
between brain MRI and cognitive metrics in MS cohorts
with a low disease burden. For example, in five cross-
sectional18,23–26 and two longitudinal studies,2,38 which
included between 43 and 81 patients in very early stages
of MS, no significant associations between MRI lesion
burden and cognitive measures were reported. Four of
these studies also examined the relationships between glo-
bal or regional brain atrophy and cognitive measures but
found no associations.2,24–26 Other studies did not find
associations between MRI and cognitive measures pre-
sumably due to the small sample size and heterogeneity
of studied cohorts.17,19–21
This study has several limitations. Cognitive function
was assessed by the BICAMS battery and PASAT. While
these tests evaluate a number of cognitive domains,
including rapid information processing, visuospatial
learning and memory, visual scanning, verbal learning
and memory, working memory, attention switching, and
calculation, several domains such as higher executive
functions, visual–spatial ability, or phonemic fluency were
not tested.1,31 However, the domains tested in the present
study are known to be most commonly impaired in
MS.1,30 A relatively low proportion of patients had abnor-
mal BICAMS outcome (27%). This could be a result of
our sample consisting of predominantly patients with a
short disease duration and low disease burden. Another
limitation is that focal MRI lesions of white matter are
only partially reflective of the disseminated pathology in
MS.3,10,11 Their specific topography rather than volume
Table 4. Interactions between brain MRI measures and demographic, clinical, or MRI grouping variables in relation to cognitive performance.
Interaction term
Symbol Digit
Modalities Test
Three-second
interval Paced
Auditory Serial
Addition Test1
Brief Visuospatial
Memory Test
Revised
California Verbal
Learning Test
Second Edition
Disease duration Disease duration x Brain
parenchymal fraction
NS NS NS NS
Disease duration x T1 lesion volume2 NS NS NS 0.28**†
Disease duration x T2 lesion volume2 NS NS 0.25**† 0.25**†
Age Age x Brain parenchymal fraction NS NS 4.08*** 2.90**†
Age x T1 lesion volume2 NS 0.63** 0.49**† 0.46**†
Age x T2 lesion volume2 NS 0.61*** 0.54*** NS
Expanded Disability
Status Scale (EDSS)
EDSS x Brain parenchymal fraction NS NS NS NS
EDSS x T1 lesion volume2 0.32**† NS 0.30**† NS
EDSS x T2 lesion volume2 0.34*** NS 0.32** NS
T2 lesion volume T2 lesion volume x Brain
parenchymal fraction
5.04*** 4.39*** 5.49*** 3.05**†
T2 lesion volume2 x T1 lesion volume2 0.89*** 0.72*** 0.59*** 0.40***
T2 lesion volume2 x T2 lesion volume2 0.80*** 0.73*** 0.60*** 0.31**†
Brain
parenchymal fraction
Brain parenchymal
fraction x Brain parenchymal fraction
4.55**† NS 8.39*** 4.27**†
Brain parenchymal
fraction x T1 lesion volume2
4.69*** 3.95** 5.09*** 3.59***
Standardized beta values of the interaction terms from adjusted multiple regression analyses are reported.
1Logistically transformed variable.
2Cox–Box transformed variable.
**P < 0.01.
***P < 0.001.
†not significant (P > 0.01) after Benjamini–Hochberg correction procedure (performed for 14 P-values).
NS, not significant interaction (P > 0.01).
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may play a role in the pathogenesis of cognitive impair-
ment. More sophisticated nonconventional MRI tech-
niques, such as magnetization transfer ratio, diffusion
tensor imaging, proton MRI spectroscopy, and functional
MRI measuring various aspects of MS pathology,3 are
likely to further improve our understanding of the associ-
ations between MRI and cognitive function at different
stages of MS. Finally, sufficiently powered longitudinal
studies are warranted to investigate the long-term associa-
tions between MRI and cognitive changes.
In conclusion, our study suggests that greater structural
brain damage corresponds to higher cognitive impairment,
especially in patients with a greater preexisting cumulative
disease burden, disease duration, or age. Although our
results may be not surprising, they have several practical
implications that have not been considered in previous
research. Firstly, patients’ MRI and clinical characteristics
should be taken into consideration when interpreting asso-
ciations between structural and cognitive changes in clinical
trials, research studies, and clinical practice.
Our results also emphasize the need for balanced recruit-
ment of participants into clinical trials in terms of radiologi-
cal disease burden. Finally, in clinical settings, the
accumulation of subclinical brain damage in MS cannot be
interpreted as “benign disease” since the clinical impact of
quantitative brain damage may be delayed. With an increas-
ing number of highly effective disease-modifying treat-
ments,39,40 the identification of patients at highest risk of
developing clinically apparent cognitive deterioration, with
the aim of preserving their cognitive capacity, belongs
among the top priorities of effective MSmanagement.
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